VYRIAD

Pharmaceuticals, namely, bio-pharmaceuticals for the treatment of cancer; stem cells for medical use; medicinal preparations for the treatment of infectious diseases and for use in oncology; pharmaceutical preparations for the treatment of immune system related diseases and disorders; pharmaceutical preparations for providing stem cell therapy; cellular pharmaceutical preparations for use in oncology and cardio-vascular diseases; living tissue in the nature of chimeric antigen receptor (CAR-T) cells for medical use; pharmaceutical preparations for use in oncology

Medical and scientific research and development in the fields of cancer treatment and oncolytic virotherapy; research and development of bio-pharmaceuticals for the treatment of cancer; medical and scientific research in the fields of genetics and oncology; research and development of technology in the fields of stem cells and stem cell therapy; development of therapeutics and cell therapies; scientific research and development of cell therapies, namely, chimeric antigen receptor T-cells (CAR-T) to cure solid tumor cancers and other cancers; medical and scientific research services in the fields of genetics, cell therapy, oncology, immuno-oncology

Cancer treatment medical services; oncolytic virotherapy medical services; stem cell therapy services; medical services in the field of oncology; medical services, namely, cellular immunotherapy treatments utilizing chimeric antigen receptor T-cells for use in treating disease, namely, the treatment of cancer